Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 17

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 17
---
 1 development for three rare / orphan brain cancers but has been de-prioritized due to resource constraints.

Our aim is to develop our
clinical assets to proof-of-concept stage before securing partners to undertake the most expensive, later stage development.

Our research and development programs may,
like MTX110, be based on one or more of our enabling technologies.

Manufacturing

We do not intend to establish
our own manufacturing capabilities. For clinical trial material we utilize GMP-certified contract manufacturers.

Commercialization

Once proof-of-concept has
been established, we intend to seek to license our products to a partner who would complete the development, and subsequently market and
sale, of the product in an agreed upon licensed territory. In addition to reimbursement of development costs, the partner would be expected
to make milestone payments based on sales targets and royalty payments.

| 7 |

Pipeline and Platform Technologies

We are actively pursuing the
development of eRapa in FAP and tolimidone in T1D. Due to resource constraints, MTX110 has been de-prioritized in the three orphan brain
cancer indications. Our development pipeline is as follows:

Our Corporate Information

We are a public limited company
incorporated under the laws of England and Wales under registered number 09216368. Our principal executive offices are located at 1 Caspian
Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom. The telephone number at our principal executive office is +44 29 20480 180. Our
authorized representative in the United States is Donald J. Puglisi of Puglisi and Associates. Our agent for service in the United States
is Donald J. Puglisi of Puglisi and Associates, located at 850 Library Avenue, Suite 204, Newark, Delaware 19711. Our Depositary Shares
are traded on the NASDAQ Capital Market under the symbol “BDRX.”

Our corporate website is located
at www.biodexapharma.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

| 8 |

Implications of Being a Foreign Private Issuer We are incorporated as a public limited company in England and Wales, and we are deemed to be a “foreign private issuer” for the purposes of the reporting rules under the Securities Exchange Act of